Background: The effect of specific antiretrovirals on inflammation is unclear.
Introduction
HIV-infected patients experience high rates of non-AIDS complications, including cardiovascular disease (CVD), which has been linked to heightened inflammation. With effective antiretroviral therapy (ART), inflammation markers overall decrease but do not normalize [1] [2] [3] [4] . Treatment with abacavir (ABC)-containing regimens has been associated with higher risk of CVD in some studies [5] [6] [7] [8] [9] [10] but not others [11] [12] [13] [14] .
Several attempts have been made to understand this potential association, with one proposed mechanism a deleterious effect of ABC on inflammation. Whereas one observational study found an association between ABC and higher inflammation markers [5] , another did not [15] . Prospective randomized studies comparing ABC to non-ABC regimens also have not demonstrated a difference in these markers [16] [17] [18] [19] . Because of the remaining uncertainty about the differential effect of ABC vs. other nucleoside reverse transcriptase inhibitors (NRTIs) on inflammation, and the potential effect of the concomitant protease inhibitor or non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy, we sought to compare changes in inflammation markers in the context of a large randomized trial.
Methods
AIDS Clinical Trials Group (ACTG) A5224s was a metabolic substudy of ACTG A5202 in which ARTnaive patients at least 16 years old with HIV-1 RNA above 1000 copies/ml were randomized in a doubleblinded fashion to co-formulated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or ABC/lamivudine (ABC/3TC), along with open-labeled efavirenz (EFV) or atazanavir/ritonavir (ATV/r). Randomization was stratified by screening HIV-1 RNA (< vs. !100 000 copies/ml). A secondary biomarker substudy of A5224s included all patients with available stored plasma at baseline and week 24 and/or 96, and was designed with the primary objective to compare the effect after 24 weeks of initiating ABC/3TC vs. TDF/FTC on inflammation and endothelial activation markers. Secondary objectives were to compare 24-week biomarker changes between EFV and ATV/r, and compare ABC/3TC vs. TDF/FTC and EFV vs. ATV/r on 96-week biomarker changes. A5224s main exclusion criteria were endocrine diseases including diabetes mellitus. The duration of the study was 96 weeks after the last patient enrolled into A5202. Each patient signed an informed consent, which was approved by each participating site's local Institutional Review Board.
As previously described [20] , the NRTI assignment was prematurely unblinded for patients with A5202 screening HIV-1 RNA at least 100 000 copies/ml because of higher rates of virologic failure with ABC/3TC regimens. Baseline smoking status was not collected in A5224s but was available on a subset of patients co-enrolled into the observational cohort ACTG A5001.
Biomarker assays
Plasma samples were stored at À808C without prior thawing until analysis. Assays were performed at Johns Hopkins Bayview Advanced Chemistry Laboratory, Baltimore, Maryland, USA. We measured high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), TNF-a, and the soluble receptors of TNF-a, (sTNFR-I, II), along with the endothelial activation markers soluble vascular cellular and intercellular adhesion molecules (sVCAM-1 and sICAM-1). hsCRP was measured using a highly sensitive ELISA (ALPCO Diagnostics, Windham, New Hampshire, USA). Other markers were measured using enzyme-immunosorbent assay (R&D Systems, Minneapolis, Minnesota, USA). Markers were measured in duplicate and values averaged for analysis. The intraassay and inter-assay precisions of these assays were 1.3-7.6% coefficient of variation (CV) (average 3.3%) and 1.83-8.95% CV (average 6.89%), respectively.
Statistical analysis
The primary objective was to compare, between pooled, randomized NRTI components (ABC/3TC vs. TDF/ FTC with third drug combined), changes from baseline to week 24 in sVCAM-1 and sTNFR-II. Other objectives were considered secondary. All analyses were initially performed using intent-to-treat principles based on randomized treatment assignment which used all available data and modifications to randomized treatment, and missing values were ignored. Supplemental as-treated analyses were performed which censored values after a change in the randomized NRTI (when comparing NRTI components) or NNRTI/protease inhibitor (when comparing NNRTI/protease inhibitor components). Comparisons used a factorial analysis approach in which, after assessing for treatment effect modification by the other component, the NRTI effect was assessed by combining EFV and ATV/r arms and vice versa. P values below 0.05 (<0.10 for assessing treatment effect modification) were considered statistically significant, and nominal values are reported without adjustment for multiple comparisons. Analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, North Carolina, USA).
Within each regimen, one-sample t-tests were used to assess mean change from baseline, whereas mean comparisons between regimen components used twosample t-tests. Analyses that adjusted for baseline factors and explored associations with biomarkers used linear regression. Due to the highly skewed distribution of the biomarker data, biomarkers were log e transformed prior to analysis. The estimated mean change from baseline of log etransformed biomarkers was exponentiated to obtain the estimated mean fold change within a component (or arm).
The estimated mean difference between components (or arms) of change from baseline in log e -transformed biomarkers were exponentiated, subtracted by 1, and multiplied by 100 to obtain the estimated percentage difference between the two mean fold changes(D), with TDF/FTC and EFV as reference groups for the comparisons.
The comparison of ABC/3TC and TDF/FTC with EFV and ATV/r combined (factorial analysis) was performed at each time point since there was no significant evidence that the NRTI effect differed at 24 or 96 weeks by the NNRTI/protease inhibitor component. Similarly, the comparison of EFV and ATV/r with ABC/3TC and TDF/FTC combined was performed.
In sensitivity analyses the intent-to-treat analyses on change in biomarkers from entry to weeks 24 and 96 were adjusted for the following prespecified baseline covariates that could affect inflammation, first individually, then jointly using linear regression: NNRTI/protease inhibitor (or NRTI components for NNRTI/protease inhibitor analyses), baseline biomarker level, sex, age, race/ethnicity, log 10 HIV-1 RNA, CD4, BMI, smoking status (when available), hypertension, fasting glucose, LDL-cholesterol, and family history of coronary artery disease (CAD).
Results

Patient characteristics
As previously detailed [21, 22] , 269 patients were randomized to one of the four regimens and were included in A5224s analysis. Of these 269 patients, 244 (91%) with available stored plasma from baseline and week 24 and/or 96 were included in this biomarker substudy. Among these 244, 61 were randomized to EFV þ TDF/FTC, 64 to EFV þABC/3TC, 57 to ATV/ r þ TDF/FTC, and 62 to ATV/r þ ABC/3TC. Baseline characteristics are summarized in Table 1 . Overall, 85% were men, 48% white non-Hispanics, and among 205 with available data, 41% were smokers. Median age was 39 years, CD4 240 cells/ml, and HIV-1 RNA 4.64 log 10 copies/ml. None of the patients had a prior history of myocardial infarction, and only one had a history of stroke. Baseline characteristics were balanced across arms, except that a larger proportion of women were randomized to EFV (18%) than ATV/r (11%), and a larger proportion of hypertensive patients were randomized to ABC/3TC (21%) than TDF/FTC (11%), and similarly, EFV (22%) than ATV/r (11%). Baseline characteristics were similar between the 244 included in the biomarker substudy and the 25 A5224s participants not included (data not shown). At week 24, 171 (70%) had HIV-1 RNA below 50 copies/ ml (70% on TDF/FTC; 70% on ABC/3TC). Among patients who had screening HIV-1 RNA at least 100 000 copies/ml, 55% on TDF/FTC and 64% on ABC/3TC had HIV-1 RNA below 50 copies/ml. Two patients experienced a myocardial infarction during the study -one at week 15 and the other at week 164. Both patients had screening HIV-1 RNA below 100 000 copies/ ml and were receiving their randomized regimen of TDF/FTC þ EFV at the time of the event.
Changes in plasma TNF-a and soluble TNF receptors (sTNFR-II co-primary endpoint) At weeks 24 and 96, there was a statistically significant decrease in TNF-a, sTNFR-I, and sTNFR-II levels within all arms (P < 0.001) ( Fig. 1 and Table 2 ), without differences between ABC/3TC and TDF/FTC or ATV/r and EFV by intent-to-treat (P ! 0.44) or as-treated analyses.
There was some evidence that the NRTI effect differed by screening HIV-1 RNA stratum for week 24 sTNFR-II (P ¼ 0.069) and TNF-a (P ¼ 0.093), and that the NNRTI/protease inhibitor effect differed for week 96 sTNFR-I (P ¼ 0.048); thus analyses were conducted within each stratum for these markers. For sTNFR-II, within the low stratum, the ABC/3TC mean fold change was marginally significantly smaller than TDF/FTC at 24 Changes in endothelial activation markers (sVCAM-1 co-primary endpoint) At weeks 24 and 96, there was a statistically significant decrease in sVCAM-1 and sICAM-1 within all arms (P 0.001) ( Fig. 1 and Table 2 ), without differences between ABC/3TC and TDF/FTC or ATV/r and EFV Table 1 . Baseline characteristics of study participants by randomized arms. at either time point by intent-to-treat (P ! 0.14) or astreated analyses. There was no significant evidence of an interaction between the NRTI components and the HIV-1 RNA stratum. However, for sVCAM-1 at week 24, there was evidence of an interaction between the NNRTI/protease inhibitor component and HIV-1 RNA stratum (P ¼ 0.047). Within the low stratum, the ATV/r estimated mean fold change was marginally larger than EFV [0.72 vs. 0.66; D ¼ 9.3% (95% CI À0.8%, 20.4%); P ¼ 0.071], whereas within the high stratum, it was similar [0.55 vs. 0.60; D ¼ À7.0% (À18.6%, 6.2%); P ¼ 0.28]. As-treated analysis showed similar results.
Changes in C-reactive protein As shown in Table 2 and Fig. 2 
Change in hsCRP (log e mg/ml), Three post-hoc sensitivity analyses were performed; the first excluding patients with suspected hypersensitivity reaction, the second excluding patients with HIV-1 RNA at least 50 copies/ml at week 24, and the third excluding the six patients with immune reconstitution syndrome. Similar results were seen by intent-to-treat and as-treated analyses for NRTI and NNRTI/protease inhibitor component comparisons. Among all patients, no differential NRTI effect was detected between patients with (n ¼ 168) and without (n ¼ 68) HIV-1 RNA below 50 copies/ml at week 24 (P ¼ 0.68). In addition, after adjustment for changes in CD4 cell counts and in BMI, the results remained unchanged. Changes by non-nucleoside reverse transcriptase inhibitor/protease inhibitor components At weeks 24 and 96, by intent-to-treat and as-treated analyses, IL-6 decreased significantly (P 0.043) in both EFVand ATV/r arms (when NRTIs combined), without significant differences for ATV/r vs. EFV (P ! 0.80).
There was no interaction between the NNRTI/protease inhibitor component and HIV-1 RNA stratum at either time point.
Changes in biomarkers adjusted for baseline covariates
The intent-to-treat analyses on change in biomarkers from entry to weeks 24 and 96 were adjusted as detailed in the statistical section. For analyses of the NRTI or NNRTI/protease inhibitor effect, all the adjusted models, alone and jointly, yielded similar results as the unadjusted analyses for all biomarkers.
Association between baseline factors and changes in biomarkers Linear regression analyses assessed the association of baseline factors with changes in biomarkers ( Table 3 ). The covariates were the same as those used in adjusted analyses, except for baseline marker level.
For CRP and IL-6, by multivariable analysis, in addition to the ABC/3TC and ATV/r effects, lower CD4 cell count was independently associated with increased 24-week hsCRP change, whereas greater HIV-1 RNA was associated with decreased IL-6. Additionally, a significant interaction between the NRTI component and HIV-1 RNA was seen for hsCRP and IL-6. Specifically, compared to TDF/FTC, per log 10 copies/ ml, HIV-1 RNA was associated with a 69.5% (1.7%, 182.6%) and 36.6% (-0.4%, 87.5%) larger mean fold change in ABC/3TC for hsCRP (1.19 vs. 0.70) and IL-6 (0.96 vs. 0.70), respectively. At 96 weeks, for both hsCRP and IL-6, male sex was associated with decreases. For the subset with smoking data (n ¼ 205), smoking was associated with 24 week increases in hsCRP and IL-6.
Discussion
This study details changes in inflammation and endothelial activation markers among patients randomized to one of the four commonly used ARTregimens. As seen in prior studies, we demonstrated that ART initiation led to a decrease in markers of TNF-a activation and endothelial activation, but not hsCRP. We also found that on average with ABC/3TC there were short-term (24 weeks) and longer-term (96 weeks) increases in hsCRP and short-term differences in IL-6 compared to 
HLA-DR
þ T-cells% with arterial stiffness [27] .
Our study supports the findings of earlier studies that initiation of effective ART results in an overall decrease in inflammation markers, with the exception of hsCRP, which remains unchanged or even increases [2, 17, 28, 29] . The reason hsCRP behaves differently from other markers remains elusive, with one potential explanation being HIV-associated subclinical hepatocyte dysfunction, as CRP is mainly produced by hepatocytes in response to IL-6. Results were unchanged after adjusting for several factors known to affect CRP, including hepatitis C [30] . Oral contraceptives have been shown to increase hsCRP [31, 32] , but excluding the four women who were on oral contraceptives (all on EFV; three on ABC/3TC) did not modify the results. Likewise, statins were shown to decrease hsCRP [33] , but excluding the 23 statin users did not affect hsCRP or IL-6 results. Regardless, hsCRP appears to be an important marker, independently associated with CVD [4, 24] , HIV progression [34] , and mortality [35] , even after adjusting for CD4 and HIV-1 RNA. However, it is unclear whether the American Heart Association (AHA) CVD risk stratification cut-offs established for HIV-uninfected populations [36] are valid in HIV. Figure 2 (c, d) shows the baseline and week 24 AHA hsCRP risk categories, without apparent shift to higher risk categories in either group.
Only limited data exist regarding the effect of specific ART on inflammation, and most focus on ABC, because of its potential link to increased CVD in some studies [5] [6] [7] [8] [9] . Others [11] [12] [13] [14] did not find such link, including A5001 [11] that included data from A5202. Studies investigating the effect of ABC on inflammation yielded conflicting results. The International Network for Strategic Initiatives in Global HIV Trials group found higher IL-6 and hsCRP, but similar TNF-a, with ABC regimens [5] , whereas the Multicenter AIDS Cohort Study cohort found similar biomarker levels, including IL-6 and hsCRP, in ABC vs. non-ABC-treated patients [15] . Moreover, studies of virologically suppressed individuals who switched their NRTIs to ABC or TDF found no differences in inflammation markers after switching [18, 19] . Furthermore, the HEAT study, which prior to the current study was the only randomized study [16] that measured inflammation markers in patients initiating their first ART regimen with ABC vs. TDFbased therapy, found no difference in these markers between the regimens. However, HEAT investigated only lopinavir/ritonavir-based therapies, whereas our study had both EFV and ATV/r as third drugs, and EFV (but not ATV/r) was found to be associated with hsCRP increase.
We found an interaction between screening HIV-1 RNA stratum and the NRTI effect so that the differences seen between ABC/3TC and TDF/FTC were larger in the high screening viral load stratum than in the lower. This observation may explain the discrepancies seen in prior biomarker studies, and specifically in prior randomized studies of virologically suppressed patients in whom no difference in markers were found between ABC and TDF regimens [18, 19] .
The mechanism by which ABC affects inflammatory pathways is not clear. In one study, ABC induced dosedependent increases in neutrophil adhesion through the activation of Mac-1, which interacts with its endothelial ligand ICAM-1 [37] . Some have suggested that analogous to other drug toxicity [38] , ABC may interfere with purine signaling pathways leading to impairment of lymphocyte activation [39] . A recent study found that ABC up-regulates pro-inflammatory cytokine mRNA transcription by stimulation of Toll-like receptor 8 signaling [40] . Others have suggested that ABC can induce a low-level hypercoagulable state by increasing platelets aggregation due to hyperactive platelets [41] , or increase fibrinolytic capacity by raising plasminogen activator inhibitor-1 levels [42] .
Although several studies have shown that CD4 cell recovery is similar after initiation of protease inhibitor vs. NNRTI regimens [43, 44] , only one study found similar decreases in sTNFR-I and II [45] with protease inhibitor vs. NNRTI regimens, but hsCRP and IL-6 were not measured. Our finding of higher CRP with EFV vs. ATV/r is consistent with a study showing that in adipocytes, EFV induces the release of higher levels of cytokines than protease inhibitors [46] .
Our study has several limitations, including decreased sample size at week 96, possible selection bias of A5224s patients who have available week 24 and/or 96 samples (possibly healthier individuals with lower inflammation), and the large number of analysis performed without adjustment for multiple comparisons, which may increase the risk of a type I error. Although the co-primary endpoints (sTNFR-II and VCAM-1) were chosen because our prior studies showed them to be associated with clinically relevant outcomes, such as incident diabetes and carotid IMT [4, 25, 28] , other markers chosen as secondary endpoints (e.g. IL-6 and hsCRP) have also been associated with mortality and CVD [24, 26] .
We have shown in a randomized study a differential treatment effect on some inflammation markers, with differences in hsCRP and IL-6 in those receiving ABC compared to TDF and EFV compared to ATV/ r-containing regimens. Further investigations are needed to duplicate these findings and clarify their clinical significance.
